PL3247394T3 - Formulacja farmaceutyczna zawierająca przeciwciało anty-EGFR - Google Patents

Formulacja farmaceutyczna zawierająca przeciwciało anty-EGFR

Info

Publication number
PL3247394T3
PL3247394T3 PL16740356T PL16740356T PL3247394T3 PL 3247394 T3 PL3247394 T3 PL 3247394T3 PL 16740356 T PL16740356 T PL 16740356T PL 16740356 T PL16740356 T PL 16740356T PL 3247394 T3 PL3247394 T3 PL 3247394T3
Authority
PL
Poland
Prior art keywords
pharmaceutical formulation
egfr antibody
egfr
antibody
formulation
Prior art date
Application number
PL16740356T
Other languages
English (en)
Inventor
Yong Woon Choi
Yoo Hoon KIM
Jungsub CHOI
Original Assignee
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corporation filed Critical Green Cross Corporation
Publication of PL3247394T3 publication Critical patent/PL3247394T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)
PL16740356T 2015-01-19 2016-01-15 Formulacja farmaceutyczna zawierająca przeciwciało anty-EGFR PL3247394T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150008677A KR101776879B1 (ko) 2015-01-19 2015-01-19 항-egfr 항체를 포함하는 약학 제제
EP16740356.7A EP3247394B1 (en) 2015-01-19 2016-01-15 Pharmaceutical formulation comprising anti-egfr antibody
PCT/KR2016/000472 WO2016117883A2 (en) 2015-01-19 2016-01-15 Pharmaceutical formulation comprising anti-egfr antibody

Publications (1)

Publication Number Publication Date
PL3247394T3 true PL3247394T3 (pl) 2021-08-30

Family

ID=56417907

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16740356T PL3247394T3 (pl) 2015-01-19 2016-01-15 Formulacja farmaceutyczna zawierająca przeciwciało anty-EGFR

Country Status (13)

Country Link
US (1) US10918717B2 (pl)
EP (1) EP3247394B1 (pl)
JP (1) JP6545806B2 (pl)
KR (1) KR101776879B1 (pl)
CN (1) CN107249634B (pl)
DK (1) DK3247394T3 (pl)
ES (1) ES2874593T3 (pl)
HR (1) HRP20210890T1 (pl)
HU (1) HUE054716T2 (pl)
PL (1) PL3247394T3 (pl)
PT (1) PT3247394T (pl)
SI (1) SI3247394T1 (pl)
WO (1) WO2016117883A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102208378B1 (ko) * 2017-08-17 2021-01-28 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
CN111665352B (zh) * 2020-06-23 2024-05-17 广州市丹蓝生物科技有限公司 一种储存剂及由其制备的抗体溶液制剂及其应用
JPWO2024058201A1 (pl) * 2022-09-16 2024-03-21
WO2025113442A1 (zh) * 2023-11-29 2025-06-05 四川科伦博泰生物医药股份有限公司 抗体制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930010489B1 (ko) 1991-06-05 1993-10-25 김경환 온상용 하우스의 지지골조
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US7635570B2 (en) 2005-04-01 2009-12-22 Salvatore Siena Epidermal growth factor receptor gene copy number
EP2029163A4 (en) * 2006-06-14 2010-08-11 Imclone Llc LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
BR112012022223B1 (pt) 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
ES2694679T3 (es) * 2012-03-27 2018-12-26 Green Cross Corporation Epitopos de antígeno de superficie receptor de factor de crecimiento epidérmico y uso de los mismos
PL2934582T3 (pl) * 2012-12-21 2020-08-10 Ichnos Sciences SA Formulacja przeciwciała anty-her2
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
SG11201601770YA (en) * 2013-09-12 2016-04-28 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof

Also Published As

Publication number Publication date
KR20160089136A (ko) 2016-07-27
EP3247394A2 (en) 2017-11-29
US20170368175A1 (en) 2017-12-28
CN107249634B (zh) 2021-11-16
WO2016117883A2 (en) 2016-07-28
SI3247394T1 (sl) 2021-08-31
EP3247394A4 (en) 2018-06-06
WO2016117883A8 (en) 2017-07-20
PT3247394T (pt) 2021-06-14
US10918717B2 (en) 2021-02-16
EP3247394B1 (en) 2021-05-12
HRP20210890T1 (hr) 2021-07-23
CN107249634A (zh) 2017-10-13
JP2018502139A (ja) 2018-01-25
HUE054716T2 (hu) 2021-09-28
ES2874593T3 (es) 2021-11-05
JP6545806B2 (ja) 2019-07-17
WO2016117883A3 (en) 2016-09-01
KR101776879B1 (ko) 2017-09-08
DK3247394T3 (da) 2021-06-07

Similar Documents

Publication Publication Date Title
ZA201804534B (en) AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-l-L1 ANTIBODY AVELUMAB
HUP1400510A1 (hu) Gyógyászati TNFalfa ellenes antitest készítmény
IL271226A (en) medical preparation
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
HUE047860T2 (hu) Ellenanyagot tartalmazó gyógyászati készítmény
IL253570B (en) Pharmacy composition
IL266537A (en) pharmaceutical preparation
ZA201807851B (en) Pharmaceutical formulation
PL3247394T3 (pl) Formulacja farmaceutyczna zawierająca przeciwciało anty-EGFR
GB201506755D0 (en) Novel pharmaceutical formulation
PL3601277T3 (pl) Preparat farmaceutyczny
IL275144A (en) Pharmacy preparation
GB201511246D0 (en) Pharmaceutical formulation
GB201719873D0 (en) Pharmaceutical formulation
GB201604545D0 (en) Novel pharmaceutical formulation